Detection of the potential pancreatic cancer marker MUC4 in serum using surface-enhanced Raman scattering.

María del Pilar Torres-González's picture
PDF versionPDF version
TitleDetection of the potential pancreatic cancer marker MUC4 in serum using surface-enhanced Raman scattering.
Publication TypeJournal Article
Year of Publication2011
AuthorsWang, G, Lipert, RJ, Jain, M, Kaur, S, Chakraboty, S, Torres, MP, Batra, SK, Brand, RE, Porter, MD
JournalAnal Chem
Date Published2011 Apr 1
KeywordsAnimals, Blood Chemical Analysis, Cell Extracts, Cell Line, Tumor, Enzyme-Linked Immunosorbent Assay, Humans, Limit of Detection, Mucin-4, Pancreatic Neoplasms, Reference Standards, Spectrum Analysis, Raman, Surface Properties, Tumor Markers, Biological

Pancreatic cancer (PC) is one of the most lethal malignancies. It has a 5-year survival rate of only 6%, owing in part to the lack of a reliable tumor marker for early diagnosis. Recent research has shown that the mucin protein MUC4 is aberrantly expressed in pancreatic adenocarcinoma cell lines and tissues but is undetectable in normal pancreas and chronic pancreatitis. Thus, the level of MUC4 in patient sera has the potential to function as a diagnostic and prognostic marker for PC. However, the measurement of MUC4 in sera using conventional test platforms (e.g., enzyme linked immunosorbent assay (ELISA) and radioimmunoassay (RIA)) has been unsuccessful. This has prevented the assessment of the utility of this protein as a possible PC marker in sera. In addressing this obstacle, the work herein examines the potential to create a simple diagnostic test for MUC4 through the development of a surface-enhanced Raman scattering (SERS)-based immunoassay, which was then used to demonstrate the first ever detection of MUC4 in cancer patient serum samples. Importantly, these measurements showed that sera from patients with PC produced a significantly higher SERS response for MUC4 compared to sera from healthy individuals and from patients with benign diseases. These results indicate that a SERS-based immunoassay can monitor MUC4 levels in patient sera, representing a much needed first step toward assessing the potential of this protein to serve as a serum marker for the early stage diagnosis of PC. This paper details these and other findings (i.e., the detection of the mucin protein CA19-9), which demonstrate that our SERS assay outperforms conventional assays (i.e., RIA and ELISA) with respect to limits of detection, readout time, and required sample volume.

Alternate JournalAnal. Chem.
PubMed ID21391573
PubMed Central IDPMC3315109
Grant ListR01 CA131944 / CA / NCI NIH HHS / United States
R01 CA131944-05 / CA / NCI NIH HHS / United States
U01 CA111294 / CA / NCI NIH HHS / United States